Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0042963 (vomiting)
 31,883 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The related central nervous system peptides neuropeptide Y and peptide YY have been found to be among the most potent endogenous stimulants of feeding behavior. We measured these neuropeptides in cerebrospinal fluid to determine whether they contributed to the pathophysiologic characteristics of anorexia and bulimia nervosa. Cerebrospinal fluid neuropeptide Y concentrations were significantly elevated in underweight anorectic patients and in many of the anorectic patients studied at intervals after weight restoration. These levels normalized in long-term weight-restored anorectic patients who had a return of normal menstrual cycles. Increased neuropeptide Y activity may contribute to several characteristic disturbances in anorexia, including menstrual dysregulation. Cerebrospinal fluid peptide YY concentrations were significantly elevated in normal-weight bulimic patients abstinent from pathological eating behavior for a month compared with themselves when actively bingeing and vomiting or compared with healthy volunteers. Increased peptide YY activity may contribute to a drive to overfeed in normal-weight bulimic patients.
 ...
PMID:Altered cerebrospinal fluid neuropeptide Y and peptide YY immunoreactivity in anorexia and bulimia nervosa. 235 Feb 7

Emesis was noted following intravenous bolus injections into dogs of a chromatographic subfraction derived from porcine small intestinal tissue extracts. The active agent was isolated from this subfraction using sequential ion-exchange and reverse-phase HPLC and demonstrated to be the recently identified regulatory peptide PYY. The threshold dose for PYY-induced emesis in the dog is less than 120 pmol/kg. Emesis was sometimes seen following large IV bolus doses of neuropeptide Y (NPY), but none was seen following IV injection of pancreatic polypeptide (PP). Dogs prepared with discrete, bilateral lesions of the area postrema were refractory to a suprathreshold emetic dose of PYY. PYY is the most potent, circulating emetic peptide identified to date.
 ...
PMID:Identification and characterization of the emetic effects of peptide YY. 274 19

Bulimia nervosa is an eating disorder characterised by recurrent episodes of binge eating and associated efforts to purge the ingested calories through self-induced vomiting, laxative or diuretic abuse, fasting or intensive exercise. The aetiopathogenesis and pathophysiology of the disorder are currently unclear. Biological bases have been proposed repeatedly, based on several lines of evidence: hunger, satiety and food choice are regulated by neurotransmitters and neuropeptides, and impairment of eating habits may be related to alterations in the secretion of these chemicals; genetic studies suggest that these neurotransmitter systems are dysfunctional in individuals with bulimia nervosa; and the frequent comorbidity of bulimia nervosa with major depressive and obsessive-compulsive disorders, conditions in which multiple alterations of brain biochemical functions have been demonstrated. Data in the literature suggest that levels of noradrenaline (norepinephrine) and serotonin (5-hydroxytryptamine; 5-HT) are lower in individuals with bulimia nervosa than in healthy controls. Levels of dopamine are similar to, or lower than, those in controls. After remission of the disorder, noradrenergic function returns to that seen in controls, whereas dopaminergic and serotonergic function rebound to levels higher than in controls. Among the neuropeptides, alterations in the levels of neuropeptide Y, peptide YY, beta-endorphin, corticotrophin-releasing hormone, somatostatin, cholecystokinin and vasopressin have been found in the symptomatic phase of bulimia nervosa, with a return to levels seen in controls after remission. Pharmacological treatment of bulimia nervosa that is directed at correction of the neurochemical alterations observed is difficult because of the complexity of the impairments. However, such treatment is necessary and should be continued long after symptomatic remission to ensure reinstitution of cerebral biochemical homeostasis.
 ...
PMID:Aetiopathogenesis and pathophysiology of bulimia nervosa: biological bases and implications for treatment. 1146 Aug 90

The effect of RCMF-magnetic therapy apparatus on signal substances was studied. The radioimmunoassay (RIA) suggested that the magnetic field increased beta-endorphin markedly in plasma. ELISA indicated that the magnetic field inhibited vomiting reaction induced by chemotherapy drug, with reversible decrease of serotonin (5-HT) level in brains, small intestine tissue and serum. Furthermore, the bioeffect of magnetic fields on 5-HT level presented a typical window effect and post-effect, and the inhibitory effect of magnetic field on the emesis was parallel to the decrease level of 5-HT. This result implied that the decrease of 5-HT might be the basis of rotating constant magnetic field (RCMF) inhibiting drug-induced emesis. The nitric acid reductase-spectrophotometry and nicotinamide adenine dinucleotide-diaphorase/arginine-vasopressin (AVP) cytochemistry technique showed that the magnetic field induced nitric oxide (NO) increase in hypothalamus and the high NO(A) level lasted for 3 hours. The results suggested that NO(A) increases after the treatment of the magnetic field in hypothalamus, which may result from strong expression of NO-ergic neuron in paraventricular hypothalamic nucleus (PVN), periventricular hypothalamic nucleus (PEN) and supraoptic nucleus (SON). The coexistence of NO and AVP may play an important role in the regulation of endocrine and neuroendocrine by the magnetic field. And our data also confirmed that the magnetic field increased the content of NO so strongly that high NO level lasted for 3 hours, also made neuropeptide Y (NPY) cell in medulla stained heavily.
 ...
PMID:Molecular mechanism of effect of rotating constant magnetic field on organisms. 1872 1